Daniela Starcevic
About Daniela Starcevic
Daniela Starcevic is the VP of Data Science and AI for Drug Development, Clinical Operations, and Revenue Growth at Bristol Myers Squibb, with extensive experience in pharmaceutical portfolio strategy and AI integration.
Company: Bristol Myers Squibb
Currently, Daniela Starcevic serves as Vice President of Data Science and AI for Drug Development, Clinical Operations, and Revenue Growth at Bristol Myers Squibb. In this role, she leads a team specializing in integrating artificial intelligence into drug development processes. Her work aims to enhance predictive insights for clinical operations and overall revenue growth.
Previous Roles at Bristol Myers Squibb
Before her current role, Daniela worked in various significant positions at Bristol Myers Squibb. From 2022 to 2023, she served as Vice President of Portfolio, Asset, and Governance Analytics and Strategy in the United States. Between 2020 and 2022, she held the role of Executive Director for R&D Pipeline and Clinical Execution Investment Strategy at the company.
Former Employment
Daniela has an extensive background in the pharmaceutical industry, including roles at other leading companies. She was Senior Director of Oncology Portfolio Investment Strategy at GSK from 2019 to 2020. From 2014 to 2019, she worked as Director of World Wide Research and Development Portfolio Strategy at Pfizer in the Greater San Diego Area. Additionally, she served as a Patent Agent at Townsend and Townsend and Crew LLP from 2005 to 2007.
Academic Background and Education
Daniela holds an impressive academic background. She earned her Ph.D. in Biological and Biomedical Sciences from Yale University. Furthermore, she completed an Executive MBA and a Master's of Management at the Stanford University Graduate School of Business.
Specializations and Expertise
Daniela specializes in pipeline planning, portfolio investment strategy, and the deployment of AI to address complex problems in healthcare and drug development. She has extensive experience in end-to-end planning and performance tracking for high-quality drug development. Her skills also extend to commercial planning and execution, effectively bridging the gap between discovery and market launch.